The Operating System for Regenerative Medicine
Cellivia unlocks access to regenerative medicine by transforming personal biological material into a lifelong therapeutic asset.
“Bank now, when you are young and healthy. Use when needed.”
The Problem
Global healthcare systems are under profound strain, designed to manage symptoms rather than restore the body at its biological root.
Aging populations with a rising chronic-disease burden
Treatments designed to manage symptoms, not address root causes
High dependence on pharmaceuticals that offer diminishing returns
Limited access to advanced regenerative therapies
Autologous regenerative medicine, using your own biological material, is among the most effective therapeutic approaches known. The evidence is consistent: no immune rejection, no epigenetic burden, and maximum personalisation.
The problem is access. Most viable biological material is discarded. Harvesting has historically been invasive and expensive. There is no global infrastructure to preserve and activate personal biological assets at scale.
Cellivia is building that infrastructure.
How We Started
Cellivia was founded on a simple observation: the future of medicine is regenerative, but most people will never have access to the biological material those therapies require.
We evaluated every major biological source (cord blood, adipose tissue, bone marrow, peripheral blood, iPSCs) and identified oral tissues, particularly gingiva and dental pulp, as an exceptional starting point: accessible during routine dental procedures, rich in mesenchymal stem cells, and scientifically validated for strong regenerative potential.
From that foundation, we are building a full-spectrum biological-asset platform, expanding into additional materials and making personalised regenerative therapy a reality for everyone.
What We’re Building
Cellivia is not a biobank, a clinic, or a therapy provider alone. It is the infrastructure layer that connects all three.
A next-generation biobanking infrastructure to collect, process, and cryogenically store biological material, beginning with oral tissues and expanding to a broader spectrum.
Biological wealth management: a personal pharmacy, preserved for when you need it.
A connected ecosystem linking patients, clinics, biobanks, laboratories, and therapy providers.
The vision: a global marketplace for personalised regenerative medicine, as easy to access as booking any healthcare service.
Personalised autologous therapies for aesthetics, orthopaedics, dentistry, hair restoration, immune modulation, and more.
Developed from the patient’s own stored biological material, activated when needed.
Biological Materials
Our scientific foundation is built on oral tissues. The roadmap extends to the full spectrum of regenerative biological material as we develop and scale.
Primary focus
Oral gum tissue, rich in mesenchymal stem cells. Can be harvested intentionally, with no extraction required.
Sourced during milk-tooth loss, wisdom-tooth removal, or orthodontic extractions (material otherwise discarded).
Planned
Body fat: a rich and accessible source of mesenchymal stem cells and regenerative factors.
Minimally invasive, with broad utility across immunological and regenerative applications.
Roadmap
Perinatal tissues, among the most potent biological material available.
A gold standard in haematological and orthopaedic applications.
The Science
Autologous therapies, using your own biological material, consistently outperform alternatives. The evidence is clear, and the logic is simple.
Your own cells are recognised by your immune system. No matching, no suppression, no rejection risk, unlike donor or allogeneic therapies.
Your cells carry your biological history. Autologous material preserves that identity, critical for long-term therapeutic precision.
Generic medicine treats populations. Autologous therapy treats you, with your own biological blueprint as the foundation.
Regenerative medicine targets the biological root of disease: actual tissue repair and cellular restoration, not symptom suppression.
The Biological Window
Biological material is most viable when collected young and in good health. Research on dental-pulp and gingival stem cells shows a measurable decline in proliferative capacity and differentiation potential in donors above 35.
This is not a preference. It is a biological window. Banking before 35 secures a high-quality, therapeutically viable asset preserved at its peak. Banking later is still possible and still valuable, but full optionality across regenerative applications is greatest when material is collected early.
Cellivia’s primary focus is the 0 to 35 age group, including families banking on behalf of children during milk-tooth loss or orthodontic procedures.
Primary collection triggers
Where We Are Now
Cellivia is currently restructuring: refining the model, forming the right clinical partnerships, and designing the global platform for personalised regenerative medicine. We are not yet operational, and we are doing this deliberately.
Contact
We welcome conversations with clinics, longevity centres, dental practices, researchers, and investors. Send us a message to learn more or explore a partnership.